1. Scrip
  2. >>COVID-19

New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost

 
• By Mandy Jackson

While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine. 

Vaccination against the new Corona Virus SARS-CoV-2: A syringe being drawn up with SARS-CoV-2 vaccination.
Pfizer and BioNTech report results from a second Phase I/II study, which was conducted in Germany • Source: Shutterstock

Pfizer Inc. and BioNTech SE released Phase I/II results for their messenger RNA (mRNA)-based COVID-19 vaccine candidate BNT162b1, from a clinical trial conducted in Germany, that showed T-cell responses that may be stronger than those observed with a competing mRNA vaccine from Moderna, Inc. The data are also consistent with neutralizing antibody data reported previously from a US study.

Pfizer and BioNTech reported results on 20 July from 60 German trial participants, including 12 patients each injected with 1mcg,...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.